Percutaneous Neurostimulation in Knee Osteoarthritis
2026年6月16日 更新者:Aliaa Mamdouh Abdelaziz Farag、Tanta University
Percutaneous Peripheral Temporary Neurostimulation in Moderate to Severe Knee Osteoarthritis
Peripheral nerve stimulation (PNS) is a drug-free pain management procedure that uses electrical impulses to target specific nerves and block pain signals.
PNS helps decrease perception of pain, providing real answers to patients dealing with chronic knee pain.
The case study discussed in this presentation is of the use of PNS targeting the superior lateral genicular nerve and the saphenous nerve for a patient with moderate to severe knee pain from osteoarthritis
研究概览
地位
招聘中
条件
研究类型
介入性
注册 (估计的)
100
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Aliaa Mamdouh Abdelaziz Farag, MD
- 电话号码:+201069468486
- 邮箱:aliaa.mamdouh@med.tanta.edu.eg
学习地点
-
-
-
Tanta、埃及
- 招聘中
- faculty of medicine, Tanta University
-
接触:
- Aliaa Mamdouh Abdelaziz Farag, MD
- 电话号码:+201069468486
- 邮箱:aliaa.mamdouh@med.tanta.edu.eg
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- adults between the ages of 30 and 70 years with a clinical diagnosis of moderate to severe knee OA who suffered knee pain.
- Patients who cannot afford intra-articular injections or radiofrequency ablation (RFA).
- patients who had failed 2 different oral pain medications and 6 weeks of physical therapy.
Exclusion Criteria:
- Patients with OA show improvement in pain after physiotherapy.
- patients evaluated by an orthopaedic surgeon and deemed to be surgical candidates due to knee pathologies other than OA.
- pregnant patients.
- patients on anticoagulation therapy, who were not permitted to stop anticoagulation.
- patients with previous trauma, neurological or endocrine diseases like diabetes mellitus, and knee tumors; and patients with inflammatory arthritis.
- people who had received an intra-articular knee injection within the last 6 months.
- Patients with tendon tears, bursitis, or calcified tendonitis as proven by imaging.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:transcutaneous nerve stimulation using a nerve stimulator to the genicular nerve block
|
temporary transcutaneous nerve stimulation using a nerve stimulator to the genicular nerve, with settings 2Hz, 0.2mA, 1ms, where the nerve is stimulated for 4 to 6 minutes.
|
|
实验性的:transcutaneous nerve stimulation using a nerve stimulator to the saphenous nerve
|
temporary transcutaneous nerve stimulation using a nerve stimulator to the saphenous nerve, with settings 2Hz, 0.2mA, 1ms, where the nerve is stimulated for 4 to 6 minutes.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in visual analogue scale after intervention.
大体时间:immediately after intervention.
|
Decrement (clinical improvement) in visual analogue scale (VAS) immediately after intervention.
The participant's knee discomfort was measured using a VAS.
Participants were asked to score their level of pain on a 100-mm horizontal line, ranging from 0 to 100.
|
immediately after intervention.
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2026年6月2日
初级完成 (估计的)
2026年11月1日
研究完成 (估计的)
2026年11月1日
研究注册日期
首次提交
2026年6月4日
首先提交符合 QC 标准的
2026年6月4日
首次发布 (实际的)
2026年6月10日
研究记录更新
最后更新发布 (实际的)
2026年6月18日
上次提交的符合 QC 标准的更新
2026年6月16日
最后验证
2026年6月1日
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
是的
IPD 计划说明
Plan to Share IPD: "Yes" Plan Description: "Data obtained through this study may be provided to qualified researchers with academic interest in scapular dyskinesis. Data or samples shared will be coded, with no PHI included. Approval of the request and execution of all applicable agreements (i.e., a material transfer agreement) are prerequisites to the sharing of data with the requesting party.
Results will be published by the investigators in academic journal.
IPD 共享时间框架
Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months.
Extensions will be considered on a case-by-case basis
IPD 共享访问标准
Access to trial IPD can be requested by qualified researchers engaging in independent scientific research and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA).
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.